Preterm Birth and PROM Testing Market Size, Share and Growth Analysis (By Test Type: Ultrasound, Biochemical Markers, Pelvic Exam, Nitazine Test, Uterine Monitoring, Pooling, Ferning Test, and Others; By End User: Diagnostic Laboratories, Hospitals, and Others) - Global Industry Analysis, Trends, Regional Outlook, and Forecast 2022 - 2030
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Preterm Birth and PROM Testing Market, By Test
7.1. Preterm Birth and PROM Testing Market, by Test Type, 2021-2030
7.1.1. Ultrasound
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Biochemical Markers
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Pelvic Exam
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Nitazine Test
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. Uterine Monitoring
7.1.5.1. Market Revenue and Forecast (2017-2030)
7.1.6. Pooling
7.1.6.1. Market Revenue and Forecast (2017-2030)
7.1.7. Ferning Test
7.1.7.1. Market Revenue and Forecast (2017-2030)
7.1.8. Others
7.1.8.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Preterm Birth and PROM Testing Market, By End User
8.1. Preterm Birth and PROM Testing Market, by End User, 2021-2030
8.1.1. Diagnostic Laboratories
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Hospitals
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Preterm Birth and PROM Testing Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Test (2017-2030)
9.1.2. Market Revenue and Forecast, by End User (2017-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.1.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.1.4.2. Market Revenue and Forecast, by End User (2017-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Test (2017-2030)
9.2.2. Market Revenue and Forecast, by End User (2017-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.2.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.2.4.2. Market Revenue and Forecast, by End User (2017-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Test (2017-2030)
9.2.5.2. Market Revenue and Forecast, by End User (2017-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Test (2017-2030)
9.2.6.2. Market Revenue and Forecast, by End User (2017-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.3.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.3.4.2. Market Revenue and Forecast, by End User (2017-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Test (2017-2030)
9.3.5.2. Market Revenue and Forecast, by End User (2017-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Test (2017-2030)
9.3.6.2. Market Revenue and Forecast, by End User (2017-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.4.2. Market Revenue and Forecast, by End User (2017-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.4.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.4.4.2. Market Revenue and Forecast, by End User (2017-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Test (2017-2030)
9.4.5.2. Market Revenue and Forecast, by End User (2017-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Test (2017-2030)
9.4.6.2. Market Revenue and Forecast, by End User (2017-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Test (2017-2030)
9.5.2. Market Revenue and Forecast, by End User (2017-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.5.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.5.4.2. Market Revenue and Forecast, by End User (2017-2030)
Chapter 10. Company Profiles
10.1. Abbott
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Qiagen N.V.
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Biosynex
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Hologic
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Cooper Surgical
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Sera Prognostics
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Medixbiochemica
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. IQ Products
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. NX Prenatal, Inc.
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Clinical Innovations, Inc.
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample